Vanda’s Hetlioz Marketing: Disease Awareness DTC, Reps For Specialty Docs
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm hopes strategy will educate patients about largely unknown condition, non-24 hour sleep-wake disorder, while using small sales force to target sleep experts.
You may also be interested in...
Specialty Pharmacies Could Be Selling Point If FDA Approves Tasimelteon
A Nov. 14 advisory committee gave near-unanimous support for Vanda’s sleep disorder drug on questions about its indication, endpoints, efficacy and safety.
Phase III Data Support Premium Pricing For Vanda’s Sleep Drug Tasimelteon
Vanda anticipates that if approved, its drug for the rare “non-24-hour” circadian rhythm disorder will command pricing in line with orphan disease treatments. Second Phase III trial has it on track for a mid-2013 submission.
Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length
Recently retired US FDA Principal Deputy Commissioner Janet Woodcock will be advising the Haystack Project, with the goal of helping rare disease organizations encourage creativity in drug development programs without jeopardizing regulatory success, Woodcock told the Pink Sheet in an interview.